{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:17:41Z","timestamp":1787062661240,"version":"build-2736575974"},"reference-count":263,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Prostate cancer (PCa) is the second most prevalent cancer among men and a major cause of cancer-related mortality worldwide. Despite an initial favorable response to hormone-based therapies, many patients ultimately develop an advanced and lethal form of the disease, referred to as castration-resistant PCa (CRPC). CRPC is associated with poor prognosis and a lack of effective curative treatments. As a result, new alternatives or improved therapeutic strategies to combat this life-threatening condition are urgently needed. Chalcones, also referred to as 1,3-diphenyl-2-propen-1-ones, have attracted significant attention because of their potent antitumor properties. Owing to their distinctive chemical structure and diverse biological activities, these compounds are promising candidates for treating various cancers, including PCa. Both naturally occurring and synthetically derived chalcones have demonstrated anticancer potential by modulating key cellular processes, including apoptosis, cell cycle regulation, cell migration, invasion, metastasis and angiogenesis, as well as major signaling pathways, such as PI3K\/Akt\/mTOR, androgen signaling, and NF-\u03baB. This review aims to outline the recent advances in the therapeutic potential of chalcone derivatives in prostate cancer, with a focus on their molecular targets, mechanisms of action, and translational relevance.<\/jats:p>","DOI":"10.3390\/ijms262412082","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:57:24Z","timestamp":1765879044000},"page":"12082","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Role of Natural Chalcones and Their Derivatives in Targeting Prostate Cancer: Recent Updates"],"prefix":"10.3390","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-9077","authenticated-orcid":false,"given":"Ola J.","family":"Hussein","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Elkhalifa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Aspetar Orthopedic and Sports Medicine Hospital, Doha P.O. Box 29222, Qatar"},{"name":"College of Health and Life Sciences, Hamad Bin Khalifa University, Doha P.O. Box 34110, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2012-4153","authenticated-orcid":false,"given":"Arij Fouzat","family":"Hassan","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8624-6869","authenticated-orcid":false,"given":"Feras","family":"Alali","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4452-3439","authenticated-orcid":false,"given":"Ala-Eddin","family":"Al Moustafa","sequence":"additional","affiliation":[{"name":"College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar"},{"name":"Oncology Department, Faculty of Medicine, McGill University, Montreal, QC H3G 2M1, Canada"},{"name":"ABS Research Review & Consultation, Montreal, QC H4L 4P8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Khalil","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Dubai Medical University, Dubai 19099, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"ref_1","unstructured":"GLOBOCAN (2025, August 15). Global Cancer Observatory (GCO): International Agency for Research on Cancer. Available online: https:\/\/gco.iarc.fr\/."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Dasgupta, P., Baade, P.D., Aitken, J.F., Ralph, N., Chambers, S.K., and Dunn, J. (2019). Geographical Variations in Prostate Cancer Outcomes: A Systematic Review of International Evidence. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00238"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.eururo.2012.02.054","article-title":"International variation in prostate cancer incidence and mortality rates","volume":"61","author":"Center","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_4","unstructured":"Sartor, A.O. (2025, August 15). Risk Factors for Prostate Cancer UpToDate: Wolters Kluwer. Available online: https:\/\/0-www.uptodate.com.mylibrary.qu.edu.qa\/contents\/risk-factors-for-prostate-cancer?search=prostate%20cancer%20risk%20factors&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H41."},{"key":"ref_5","unstructured":"SEER (2025, August 13). Cancer Stat Facts: Prostate Cancer: National Cancer Institute, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Haiman, C.A., Chen, G.K., Blot, W.J., Strom, S.S., Berndt, S.I., Kittles, R.A., Rybicki, B.A., Isaacs, W.B., Ingles, S.A., and Stanford, J.L. (2011). Characterizing Genetic Risk at Known Prostate Cancer Susceptibility Loci in African Americans. PLoS Genet., 7.","DOI":"10.1371\/journal.pgen.1001387"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1158\/1078-0432.CCR-18-0370","article-title":"Family history of breast or prostate cancer and prostate cancer risk","volume":"24","author":"Barber","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0090-4295(00)00780-9","article-title":"Family history and the risk of prostate cancer","volume":"56","author":"Kalish","year":"2000","journal-title":"Urology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","article-title":"Prostate cancer","volume":"387","author":"Attard","year":"2016","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/bjc.2011.383","article-title":"BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: Implications for genetic testing in prostate cancer patients","volume":"105","author":"Leongamornlert","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/318181","article-title":"Variation in cancer risks, by mutation position, in BRCA2 mutation carriers","volume":"68","author":"Thompson","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"ref_12","unstructured":"SEER (2020, August 15). Cancer Stat Facts: Common Cancer Sites: National Cancer Institute, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/common.html."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Crona, D.J., and Whang, Y.E. (2017). Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. Cancers, 9.","DOI":"10.3390\/cancers9060067"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7762","DOI":"10.1021\/acs.chemrev.7b00020","article-title":"Chalcone: A privileged structure in medicinal chemistry","volume":"117","author":"Zhuang","year":"2017","journal-title":"Chem. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Dhaliwal, J.S., Moshawih, S., Goh, K.W., Loy, M.J., Hossain, M.S., Hermansyah, A., Kotra, V., Kifli, N., Goh, H.P., and Dhaliwal, S.K.S. (2022). Pharmacotherapeutics Applications and Chemistry of Chalcone Derivatives. Molecules, 27.","DOI":"10.3390\/molecules27207062"},{"key":"ref_16","first-page":"118982","article-title":"Signaling pathways and proteins targeted by antidiabetic chalcones","volume":"284","author":"Isaac","year":"2020","journal-title":"Life Sci."},{"key":"ref_17","first-page":"149","article-title":"Antimicrobial Screening, in Silico Studies and QSAR of Chalcone-based 1,4-disubstituted 1,2,3-triazole Hybrids","volume":"71","author":"Yadav","year":"2020","journal-title":"Drug Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3923\/pjbs.2013.1368.1372","article-title":"Synthesis and evaluation of chalcone analogues based pyrimidines as angiotensin converting enzyme inhibitors","volume":"16","author":"Bukhari","year":"2013","journal-title":"Pak. J. Biol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1080\/1061186X.2020.1853759","article-title":"A comprehensive review on the antiviral activities of chalcones","volume":"29","author":"Elkhalifa","year":"2021","journal-title":"J. Drug Target."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s12263-011-0210-5","article-title":"Dietary chalcones with chemopreventive and chemotherapeutic potential","volume":"6","author":"Orlikova","year":"2011","journal-title":"Genes. Nutr."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Feng, Q., and He, B. (2019). Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00858"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","article-title":"Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American society of clinical oncology practice guideline","volume":"25","author":"Loblaw","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/107327481502200114","article-title":"Current and emerging therapies for bone metastatic castration-resistant prostate cancer","volume":"22","author":"Frieling","year":"2015","journal-title":"Cancer Control"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/MOU.0b013e32835e2253","article-title":"Castrate-resistant prostate cancer: Postdocetaxel management","volume":"23","author":"Zhao","year":"2013","journal-title":"Curr. Opin. Urol."},{"key":"ref_26","unstructured":"Hussain, A., and Dawson, M.A. (2025, August 15). Chemotherapy in Advanced Castration-Resistant Prostate Cancer UpToDate: Wolters Kluwer. Available online: https:\/\/0-www.uptodate.com.mylibrary.qu.edu.qa\/contents\/chemotherapy-in-advanced-castration-resistant-prostate-cancer?sectionName=Chemotherapy-na%C3%AFve%20patients&search=castration%20resistant&topicRef=112896&anchor=H8&source=see_link#H8."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s40266-019-00643-2","article-title":"Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice","volume":"36","author":"Crombag","year":"2019","journal-title":"Drugs Aging"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2147\/CMAR.S40601","article-title":"Presentation and management of docetaxel-related adverse effects in patients with breast cancer","volume":"6","author":"Ho","year":"2014","journal-title":"Cancer Manag. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/med.21548","article-title":"Molecules targeting the androgen receptor (AR) signaling axis beyond the AR-Ligand binding domain","volume":"39","author":"Elshan","year":"2019","journal-title":"Med. Res. Rev."},{"key":"ref_32","unstructured":"Dawson, N.A., and Leger, P. (2025, August 15). Overview of the Treatment of Castration-Resistant Prostate Cancer (CRPC) UpToDate: Wolters Kluwer. Available online: https:\/\/0-www.uptodate.com.mylibrary.qu.edu.qa\/contents\/overview-of-the-treatment-of-castration-resistant-prostate-cancer-crpc?search=castration-resistant%20prostate%20cancer&source=search_result&selectedTitle=1~64&usage_type=default&display_rank=1."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"Oudard","year":"2010","journal-title":"Lancet"},{"key":"ref_34","unstructured":"(FDA) USFaDA (2025, August 15). 2010 Notifications FDA2010, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/2010-notifications."},{"key":"ref_35","unstructured":"NCCN (2025, August 15). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer: NCCN. Available online: https:\/\/www2.tri-kobe.org\/nccn\/guideline\/urological\/english\/prostate.pdf."},{"key":"ref_36","unstructured":"(2020, August 26). Sipuleucel-T: Drug Information: Wolters Kluwer. Available online: https:\/\/0-www.uptodate.com.mylibrary.qu.edu.qa\/contents\/sipuleucel-t-drug-information?search=castration-resistant%20prostate%20cancer&topicRef=112896&source=see_link."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1309\/G6PR-Y774-X738-FG2K","article-title":"Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores","volume":"117","author":"Goldstein","year":"2002","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_38","unstructured":"(2020, August 26). Radium-223: Drug Information: Wolters Kluwer. Available online: https:\/\/www.google.com\/search?q=wolters+kluwer&oq=wolter&aqs=chrome.0.69i59j69i57j0l3j46j69i60j69i61.1928j0j7&sourceid=chrome&ie=UTF-8."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase III trial-FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Pozas, J., \u00c1lvarez Rodr\u00edguez, S., Fern\u00e1ndez, V.A., Burgos, J., Santoni, M., Manneh Kopp, R., Molina-Cerrillo, J., and Alonso-Gordoa, T. (2022). Androgen Receptor Signaling Inhibition in Advanced Castration Resistance Prostate Cancer: What Is Expected for the Near Future?. Cancers, 14.","DOI":"10.3390\/cancers14246071"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth","volume":"68","author":"Montgomery","year":"2008","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1002\/1097-0142(19931215)72:12+<3816::AID-CNCR2820721711>3.0.CO;2-3","article-title":"Mechanism of action and pure antiandrogenic properties of flutamide","volume":"72","author":"Labrie","year":"1993","journal-title":"Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1056\/NEJMe1006300","article-title":"New Therapies for Castration-Resistant Prostate Cancer","volume":"363","author":"Longo","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1021\/jm00013a022","article-title":"Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): Potential agents for the treatment of prostatic cancer","volume":"38","author":"Potter","year":"1995","journal-title":"J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3109\/21681805.2013.860189","article-title":"Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate","volume":"48","author":"Thomsen","year":"2014","journal-title":"Scand. J. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kita, Y., Goto, T., Akamatsu, S., Yamasaki, T., Inoue, T., Ogawa, O., and Kobayashi, T. (2018). Castration-resistant prostate cancer refractory to second-generation androgen receptor axis-targeted agents: Opportunities and challenges. Cancers, 10.","DOI":"10.3390\/cancers10100345"},{"key":"ref_51","unstructured":"(FDA) USFaDA (2025, August 15). FDA Grants Accelerated Approval to Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer, Available online: https:\/\/www.fda.gov\/drugs\/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_53","unstructured":"(FDA) USFaDA (2025, August 15). FDA Approves Olaparib for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer."},{"key":"ref_54","unstructured":"(FDA) USFaDA (2020, August 15). FDA Approves First Cancer Treatment for Any Solid Tumor with a Specific Genetic Feature, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-cancer-treatment-any-solid-tumor-specific-genetic-feature."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00064","article-title":"Beyond the Androgen Receptor: Targeting Actionable Drivers of Prostate Cancer","volume":"1","author":"Nelson","year":"2017","journal-title":"JCO Precis. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2014.01.018","article-title":"The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer","volume":"66","author":"Schweizer","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/pcan.2014.53","article-title":"Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and\/or docetaxel","volume":"18","author":"Cheng","year":"2015","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/annonc\/mds119","article-title":"Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: Clinical evidence for cross-resistance?","volume":"23","author":"Mezynski","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Xiao, J., Sarker, S.D., and Asakawa, Y. (2019). Chalcones in Diets. Handbook of Dietary Phytochemicals, Springer.","DOI":"10.1007\/978-981-13-1745-3"},{"key":"ref_61","first-page":"223","article-title":"Chemical and Structural Properties of Chalcones I","volume":"36","author":"Ertan","year":"2014","journal-title":"FABAD J. Pharm. Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157488410790410579","article-title":"Trends in utilization of the pharmacological potential of chalcones","volume":"5","author":"Batovska","year":"2010","journal-title":"Curr. Clin. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"109315","DOI":"10.1016\/j.cbi.2020.109315","article-title":"Antioxidant and anti-inflammatory effects of hesperidin methyl chalcone in experimental ulcerative colitis","volume":"333","author":"Guazelli","year":"2021","journal-title":"Chem. Biol. Interact."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"111954","DOI":"10.1016\/j.ejmech.2019.111954","article-title":"Design, synthesis, and validation of novel nitrogen-based chalcone analogs against triple negative breast cancer","volume":"187","author":"Elkhalifa","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e27002","DOI":"10.1016\/j.heliyon.2024.e27002","article-title":"The effect of novel nitrogen-based chalcone analogs on colorectal cancer cells: Insight into the molecular pathways","volume":"10","author":"Hassan","year":"2024","journal-title":"Heliyon"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejmech.2015.05.004","article-title":"Anti-cancer chalcones: Structural and molecular target perspectives","volume":"98","author":"Mahapatra","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"7228","DOI":"10.1021\/jm901278z","article-title":"Structure-activity relationship studies of chalcone leading to 3-hydroxy-4,3\u2032,4\u2032,5\u2032-tetramethoxychalcone and its analogues as potent nuclear factor kappaB inhibitors and their anticancer activities","volume":"52","author":"Srinivasan","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7651047","DOI":"10.1155\/2016\/7651047","article-title":"Chalcone Scaffold in Anticancer Armamentarium: A Molecular Insight","volume":"2016","author":"Das","year":"2016","journal-title":"J. Toxicol."},{"key":"ref_69","first-page":"422","article-title":"Heterocyclic chalcone analogues as potential anticancer agents","volume":"13","author":"Sharma","year":"2013","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_70","first-page":"47","article-title":"Chapter 2\u2014Natural and Synthetic Chalcones: Tools for the Study of Targets of Action\u2014Insulin Secretagogue or Insulin Mimetic?","volume":"39","year":"2013","journal-title":"Studies in Natural Products Chemistry"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s11101-011-9211-7","article-title":"Chalcone synthase and its functions in plant resistance","volume":"10","author":"Dao","year":"2011","journal-title":"Phytochem. Rev."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1146\/annurev.pp.40.060189.002023","article-title":"Physiology and Molecular Biology of Phenylpropanoid Metabolism","volume":"40","author":"Hahlbrock","year":"1989","journal-title":"Annu. Rev. Plant Physiol. Plant Mol. Biol."},{"key":"ref_73","first-page":"546","article-title":"A Review on Natural Chalcones as Update","volume":"11","author":"Banoth","year":"2020","journal-title":"Int. J. Pharm. Sci. Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1517\/13543776.14.12.1669","article-title":"Recent advances in therapeutic chalcones","volume":"14","author":"Ni","year":"2004","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Gomes, M.N., Muratov, E.N., Pereira, M., Peixoto, J.C., Rosseto, L.P., Cravo, P.V.L., Andrade, C.H., and Neves, B.J. (2017). Chalcone Derivatives: Promising Starting Points for Drug Design. Molecules, 22.","DOI":"10.3390\/molecules22081210"},{"key":"ref_76","first-page":"525","article-title":"Quality of life improvement in Latin American patients suffering from chronic venous disorder using a combination of Ruscus aculeatus and hesperidin methyl-chalcone and ascorbic acid (quality study)","volume":"29","author":"Guex","year":"2010","journal-title":"Int. Angiol."},{"key":"ref_77","first-page":"111","article-title":"Combination of Ruscus aculeatus extract, hesperidin methyl chalcone and ascorbic acid: A comprehensive review of their pharmacological and clinical effects and of the pathophysiology of chronic venous disease","volume":"35","author":"Allaert","year":"2016","journal-title":"Int. Angiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"9445","DOI":"10.1016\/j.tet.2010.09.089","article-title":"Synthesis of chalcones and flavanones using Julia\u2013Kocienski olefination","volume":"66","author":"Kumar","year":"2010","journal-title":"Tetrahedron"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/13543776.2019.1613374","article-title":"An updated patent review of therapeutic applications of chalcone derivatives (2014\u2013present)","volume":"29","author":"Asati","year":"2019","journal-title":"Expert. Opin. Ther. Pat."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2174\/1568009614666140122160515","article-title":"Molecular targeted approaches to cancer therapy and prevention using chalcones","volume":"14","author":"Jandial","year":"2014","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/1574892809666140819153902","article-title":"Advances in chalcones with anticancer activities","volume":"10","author":"Karthikeyan","year":"2015","journal-title":"Recent. Pat. Anticancer Drug Discov."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/med.21698","article-title":"Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure-activity relationship","volume":"40","author":"Gao","year":"2020","journal-title":"Med. Res. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"389","DOI":"10.21873\/anticanres.16174","article-title":"Chalcone Derivatives Suppress Proliferation and Migration of Castration-resistant Prostate Cancer Cells Through FAK-mediated DNA Damage","volume":"43","author":"Xiao","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Michalkova, R., Mirossay, L., Kello, M., Mojzisova, G., Baloghova, J., Podracka, A., and Mojzis, J. (2023). Anticancer Potential of Natural Chalcones: In Vitro and In Vivo Evidence. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210354"},{"key":"ref_85","first-page":"420","article-title":"The correlation between cancer incidence and kava consumption","volume":"59","author":"Steiner","year":"2000","journal-title":"Hawaii Med. J."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bjc.1972.33","article-title":"Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics","volume":"26","author":"Kerr","year":"1972","journal-title":"Br. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/jcb.21707","article-title":"Dysregulation of apoptotic signaling in cancer: Molecular mechanisms and therapeutic opportunities","volume":"104","author":"Plati","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s11523-006-0034-1","article-title":"Apoptosis: Mechanisms and implications for cancer therapeutics","volume":"1","author":"Mita","year":"2006","journal-title":"Target. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.semcancer.2015.03.001","article-title":"Broad targeting of resistance to apoptosis in cancer","volume":"35","author":"Mohammad","year":"2015","journal-title":"Semin. Cancer Biol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1046\/j.1442-2042.1999.00102.x","article-title":"Effect of Bcl-2 overexpression in human prostate cancer cells in vitro and in vivo","volume":"6","author":"Kajiwara","year":"1999","journal-title":"Int. J. Urol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1101\/gad.12.11.1551","article-title":"Proteases to die for","volume":"12","author":"Cryns","year":"1998","journal-title":"Genes Dev."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/cncr.23318","article-title":"Mechanisms of apoptosis resistance and treatment strategies to overcome them in hormone-refractory prostate cancer","volume":"112","author":"Uzzo","year":"2008","journal-title":"Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/jcb.20634","article-title":"Apoptosis evasion: The role of survival pathways in prostate cancer progression and therapeutic resistance","volume":"97","author":"McKenzie","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"ref_94","first-page":"1227","article-title":"Loss of caspase-1 and caspase-3 protein expression in human prostate cancer","volume":"61","author":"Winter","year":"2001","journal-title":"Cancer Res."},{"key":"ref_95","first-page":"2121","article-title":"Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes","volume":"11","author":"Kagan","year":"1995","journal-title":"Oncogene"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.3892\/mmr.2014.2504","article-title":"Death receptor 5 expression is inversely correlated with prostate cancer progression","volume":"10","author":"Vega","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: From pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jnutbio.2005.11.006","article-title":"Isoliquiritigenin induces apoptosis by depolarizing mitochondrial membranes in prostate cancer cells","volume":"17","author":"Jung","year":"2006","journal-title":"J. Nutr. Biochem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bmc.2018.10.045","article-title":"Design, synthesis and QSAR study of 2\u2032-hydroxy-4\u2032-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway","volume":"27","author":"Marquina","year":"2019","journal-title":"Bioorganic Med. Chem."},{"key":"ref_100","first-page":"3333","article-title":"Growth inhibitory and apoptosis-inducing effects of xanthohumol, a prenylated chalone present in hops, in human prostate cancer cells","volume":"30","author":"Deeb","year":"2010","journal-title":"Anticancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12964-019-0338-2","article-title":"Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation","volume":"17","author":"Li","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"K\u0142\u00f3sek, M., Mertas, A., Kr\u00f3l, W., Jaworska, D., Szymszal, J., and Szliszka, E. (2016). Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells after treatment with Xanthohumol-A natural compound present in Humulus lupulus L.. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17060837"},{"key":"ref_103","first-page":"274","article-title":"Anti-tumor activity of benzylideneacetophenone derivatives via proteasomal inhibition in prostate cancer cells","volume":"71","author":"Lee","year":"2016","journal-title":"Pharmazie"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.3390\/molecules15085336","article-title":"Chalcones and dihydrochalcones augment TRAIL-mediated apoptosis in prostate cancer cells","volume":"15","author":"Szliszka","year":"2010","journal-title":"Molecules"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms11010001","article-title":"Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells","volume":"11","author":"Szliszka","year":"2009","journal-title":"Int. J. Mol. Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/CAD.0000000000000163","article-title":"2\u2032-Hydroxy-4-methylsulfonylchalcone enhances TRAIL-induced apoptosis in prostate cancer cells","volume":"26","author":"Ismail","year":"2015","journal-title":"Anticancer Drugs"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ejmech.2018.12.014","article-title":"Synthesis of new chalcone-based homoserine lactones and their antiproliferative activity evaluation","volume":"163","author":"Yu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2008.02.001","article-title":"TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them","volume":"11","author":"Thorburn","year":"2008","journal-title":"Drug Resist. Updat."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Ding, L., Cao, J., Lin, W., Chen, H., Xiong, X., Ao, H., Yu, M., Lin, J., and Cui, Q. (2020). The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21061960"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nrd4504","article-title":"The history and future of targeting cyclin-dependent kinases in cancer therapy","volume":"14","author":"Asghar","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.pharmthera.2013.01.011","article-title":"Targeting cell cycle regulation in cancer therapy","volume":"138","author":"Miranda","year":"2013","journal-title":"Pharmacol. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/sj.bjc.6600458","article-title":"Targeting the cell cycle for cancer therapy","volume":"87","author":"Carnero","year":"2002","journal-title":"Br. J. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/(SICI)1097-0045(19990215)38:3<175::AID-PROS1>3.0.CO;2-#","article-title":"Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival","volume":"38","author":"Aaltomaa","year":"1999","journal-title":"Prostate"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/sj.bjc.6603615","article-title":"Impact of differential cyclin D1 expression and localisation in prostate cancer","volume":"96","author":"Comstock","year":"2007","journal-title":"Br. J. Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1692658","DOI":"10.1155\/2020\/1692658","article-title":"Differential Expression and Prognostic Value of Cytoplasmic and Nuclear Cyclin D1 in Prostate Cancer","volume":"2020","author":"Cao","year":"2020","journal-title":"BioMed Res. Int."},{"key":"ref_117","first-page":"1474","article-title":"Combined Loss of PTEN and p27 Expression Is Associated with Tumor Cell Proliferation by Ki-67 and Increased Risk of Recurrent Disease in Localized Prostate Cancer","volume":"9","author":"Halvorsen","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"4842","DOI":"10.1021\/acsomega.0c05822","article-title":"Bicyclic Chalcones as Mitotic Inhibitors for Overcoming Androgen Receptor-Independent and Multidrug-Resistant Prostate Cancer","volume":"6","author":"Saito","year":"2021","journal-title":"ACS Omega"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"153514","DOI":"10.1016\/j.phymed.2021.153514","article-title":"Neoisoliquiritin exerts tumor suppressive effects on prostate cancer by repressing androgen receptor activity","volume":"85","author":"Chen","year":"2021","journal-title":"Phytomedicine"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.21873\/anticanres.16411","article-title":"Novel \u03b1-Trifluoromethyl Chalcone Exerts Antitumor Effects Against Prostate Cancer Cells","volume":"43","author":"Shimada","year":"2023","journal-title":"Anticancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Saito, Y., Mizokami, A., Izumi, K., Naito, R., Goto, M., and Nakagawa-Goto, K. (2021). \u03b1-Trifluoromethyl Chalcones as Potent Anticancer Agents for Androgen Receptor-Independent Prostate Cancer. Molecules, 26.","DOI":"10.3390\/molecules26092812"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"113586","DOI":"10.1016\/j.ejmech.2021.113586","article-title":"Synthesis and biological evaluation of chalcone-polyamine conjugates as novel vectorized agents in colorectal and prostate cancer chemotherapy","volume":"222","author":"Rioux","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.bbrc.2004.07.094","article-title":"Licochalcone-A, a novel flavonoid isolated from licorice root (Glycyrrhiza glabra), causes G2 and late-G1 arrests in androgen-independent PC-3 prostate cancer cells","volume":"322","author":"Fu","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bioorg.2019.01.023","article-title":"Discovery of novel chalcone-dithiocarbamates as ROS-mediated apoptosis inducers by inhibiting catalase","volume":"86","author":"Fu","year":"2019","journal-title":"Bioorganic Chem."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/pros.21165","article-title":"Methoxychalcone induces cell-cycle arrest and apoptosis in human hormone-resistant prostate cancer cells through PI 3-kinase-independent inhibition of mTOR pathways","volume":"70","author":"Sun","year":"2010","journal-title":"Prostate"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/jmf.2008.0039","article-title":"Induction of cell cycle arrest in prostate cancer cells by the dietary compound isoliquiritigenin","volume":"12","author":"Lee","year":"2009","journal-title":"J. Med. Food"},{"key":"ref_127","first-page":"3689","article-title":"A new chalcone derivative (E)-3-(4-methoxyphenyl)-2-methyl-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one suppresses prostate cancer involving p53-mediated cell cycle arrests and apoptosis","volume":"32","author":"Zhang","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Alam, M.J., Alam, O., Perwez, A., Rizvi, M.A., Naim, M.J., Naidu, V.G.M., Imran, M., Ghoneim, M.M., Alshehri, S., and Shakeel, F. (2022). Design, Synthesis, Molecular Docking, and Biological Evaluation of Pyrazole Hybrid Chalcone Conjugates as Potential Anticancer Agents and Tubulin Polymerization Inhibitors. Pharmaceuticals, 15.","DOI":"10.3390\/ph15030280"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"21296","DOI":"10.1016\/S0021-9258(19)30078-X","article-title":"Interaction of tubulin and cellular microtubules with the new antitumor drug MDL 27048. A powerful and reversible microtubule inhibitor","volume":"264","author":"Peyrot","year":"1989","journal-title":"J. Biol. Chem."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.ejmech.2018.08.069","article-title":"5\u2032-Chloro-2,2\u2032-dihydroxychalcone and related flavanoids as treatments for prostate cancer","volume":"157","author":"Saito","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/cbdd.12738","article-title":"Synthesis and Biological Evaluation of 1,2,3-triazole tethered Pyrazoline and Chalcone Derivatives","volume":"88","author":"Hussaini","year":"2016","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"113288","DOI":"10.1016\/j.jpba.2020.113288","article-title":"Flavokawain A inhibits prostate cancer cells by inducing cell cycle arrest and cell apoptosis and regulating the glutamine metabolism pathway","volume":"186","author":"Wang","year":"2020","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1021\/acs.jnatprod.5b00908","article-title":"Texas native plants yield compounds with cytotoxic activities against prostate cancer cells","volume":"79","author":"Shaffer","year":"2016","journal-title":"J. Nat. Prod."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nm1469","article-title":"Tumor metastasis: Mechanistic insights and clinical challenges","volume":"12","author":"Steeg","year":"2006","journal-title":"Nat. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1158\/1541-7786.MCR-10-0568","article-title":"Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation","volume":"9","author":"Yao","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"ref_136","unstructured":"Schatten, H. (2018). Epithelial-mesenchymal transition (emt) and prostate cancer. Cell & Molecular Biology of Prostate Cancer: Updates, Insights and New Frontiers, Springer International Publishing."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"35376","DOI":"10.18632\/oncotarget.15686","article-title":"Epithelial-mesenchymal transition in prostate cancer: An overview","volume":"8","author":"Montanari","year":"2017","journal-title":"Oncotarget"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"7938280","DOI":"10.1155\/2020\/7938280","article-title":"The Prospect of Identifying Resistance Mechanisms for Castrate-Resistant Prostate Cancer Using Circulating Tumor Cells: Is Epithelial-to-Mesenchymal Transition a Key Player?","volume":"2020","author":"Khan","year":"2020","journal-title":"Prostate Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Chen, C., Huang, S., Chen, C.L., Su, S.B., and Fang, D.D. (2019). Isoliquiritigenin Inhibits Ovarian Cancer Metastasis by Reversing Epithelial-to-Mesenchymal Transition. Molecules, 24.","DOI":"10.3390\/molecules24203725"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1002\/jcb.27460","article-title":"Novel TGF-\u03b21 inhibitor antagonizes TGF-\u03b21-induced epithelial-mesenchymal transition in human A549 lung cancer cells","volume":"120","author":"Jeong","year":"2019","journal-title":"J. Cell Biochem."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.tiv.2010.08.002","article-title":"Butein suppresses the expression of nuclear factor-kappa B-mediated matrix metalloproteinase-9 and vascular endothelial growth factor in prostate cancer cells","volume":"24","author":"Moon","year":"2010","journal-title":"Toxicol. Vitr."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Ma, Y., Xu, B., Yu, J., Huang, L., Zeng, X., Shen, X., Ren, C., Ben-David, Y., and Luo, H. (2020). Fli-1 activation through targeted promoter activity regulation using a novel 3\u2032, 5\u2032-diprenylated chalcone inhibits growth and metastasis of prostate cancer cells. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062216"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jnutbio.2008.06.005","article-title":"Isoliquiritigenin inhibits migration and invasion of prostate cancer cells: Possible mediation by decreased JNK\/AP-1 signaling","volume":"20","author":"Kwon","year":"2009","journal-title":"J. Nutr. Biochem."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Porta, C., Paglino, C., and Mosca, A. (2014). Targeting PI3K\/Akt\/mTOR Signaling in Cancer. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00064"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/2159-8290.CD-17-0867","article-title":"Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth","volume":"8","author":"Pearson","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Shorning, B.Y., Dass, M.S., Smalley, M.J., and Pearson, H.B. (2020). The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124507"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/biof.5520280302","article-title":"Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells","volume":"28","author":"Jung","year":"2006","journal-title":"Biofactors"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1158\/0008-5472.CAN-09-0597","article-title":"Dietary feeding of dibenzoylmethane inhibits prostate cancer in transgenic adenocarcinoma of the mouse prostate model","volume":"69","author":"Khor","year":"2009","journal-title":"Cancer Res."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"8266","DOI":"10.1021\/jf901054c","article-title":"Licorice and licochalcone-A induce autophagy in LNCaP prostate cancer cells by suppression of Bcl-2 expression and the mTOR pathway","volume":"57","author":"Yo","year":"2009","journal-title":"J. Agric. Food Chem."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Horta, B., Freitas-Silva, J., Silva, J., Dias, F., Teixeira, A.L., Medeiros, R., Cidade, H., Pinto, M., and Cerqueira, F. (2023). Antitumor Effect of Chalcone Derivatives against Human Prostate (LNCaP and PC-3), Cervix HPV-Positive (HeLa) and Lymphocyte (Jurkat) Cell Lines and Their Effect on Macrophage Functions. Molecules, 28.","DOI":"10.3390\/molecules28052159"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2147\/vhrm.2006.2.2.97","article-title":"Clinical implications of angiogenesis in cancers","volume":"2","author":"Pang","year":"2006","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1177\/1947601911423031","article-title":"Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies","volume":"2","author":"Shibuya","year":"2011","journal-title":"Genes Cancer"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijrobp.2006.08.077","article-title":"Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome","volume":"67","author":"Green","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Bender, R.J., and Mac Gabhann, F. (2015). Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis. BMC Syst. Biol., 9.","DOI":"10.1186\/s12918-015-0201-z"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Melegh, Z., and Oltean, S. (2019). Targeting Angiogenesis in Prostate Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112676"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2015.65.3154","article-title":"A randomized phase II trial of short-course androgen deprivation therapy with or without Bevacizumab for patients with recurrent prostate cancer after definitive local therapy","volume":"34","author":"McKay","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","article-title":"Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401","volume":"30","author":"Kelly","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1470-2045(13)70184-0","article-title":"Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): A phase 3, double-blind randomised trial","volume":"14","author":"Tannock","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2012.48.5268","article-title":"Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer","volume":"32","author":"Michaelson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1158\/1078-0432.CCR-10-1928","article-title":"Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: Results of a phase I\/II double-blinded, randomized study","volume":"16","author":"Keizman","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.2174\/1381612826666200206095400","article-title":"Novel Polymethoxylated Chalcones as Potential Compounds Against KRAS-Mutant Colorectal Cancers","volume":"26","author":"Mahmoud","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"9103","DOI":"10.18632\/aging.103178","article-title":"A novel 3\u2032,5\u2032-diprenylated chalcone induces concurrent apoptosis and GSDME-dependent pyroptosis through activating PKC\u03b4\/JNK signal in prostate cancer","volume":"12","author":"Zhang","year":"2020","journal-title":"Aging"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/aps.2014.18","article-title":"Androgen receptor: Structure, role in prostate cancer and drug discovery","volume":"36","author":"Tan","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"key":"ref_169","first-page":"1483","article-title":"Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer","volume":"27","author":"Jackson","year":"2007","journal-title":"Anticancer Res."},{"key":"ref_170","first-page":"405","article-title":"Down-regulation of androgen-receptor and PSA by phytochemicals","volume":"32","author":"Chen","year":"2008","journal-title":"Int. J. Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.bmcl.2008.12.089","article-title":"Syntheses and potential anti-prostate cancer activities of ionone-based chalcones","volume":"19","author":"Zhou","year":"2009","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_172","doi-asserted-by":"crossref","unstructured":"Aggarwal, V., Tuli, H.S., Varol, A., Thakral, F., Yerer, M.B., Sak, K., Varol, M., Jain, A., Khan, M.A., and Sethi, G. (2019). Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements. Biomolecules, 9.","DOI":"10.3390\/biom9110735"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.freeradbiomed.2010.09.006","article-title":"Oxidative stress, inflammation, and cancer: How are they linked?","volume":"49","author":"Reuter","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1158\/0008-5472.CAN-07-5259","article-title":"Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype","volume":"68","author":"Kumar","year":"2008","journal-title":"Cancer Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.biopha.2011.06.003","article-title":"Oxidative stress and antioxidant status in prostate cancer patients: Relation to Gleason score, treatment and bone metastasis","volume":"65","author":"Battisti","year":"2011","journal-title":"Biomed. Pharmacother."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1038\/onc.2014.302","article-title":"Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression","volume":"34","author":"Jin","year":"2015","journal-title":"Oncogene"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Khurana, N., and Sikka, S.C. (2018). Targeting Crosstalk between Nrf-2, NF-\u03baB and Androgen Receptor Signaling in Prostate Cancer. Cancers, 10.","DOI":"10.3390\/cancers10100352"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Staal, J., and Beyaert, R. (2018). Inflammation and NF-\u03baB Signaling in Prostate Cancer: Mechanisms and Clinical Implications. Cells, 7.","DOI":"10.3390\/cells7090122"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.3892\/ijo.2013.2024","article-title":"Novel methylsulfonyl chalcones as potential antiproliferative drugs for human prostate cancer: Involvement of the intrinsic pathway of apoptosis","volume":"43","author":"Ismail","year":"2013","journal-title":"Int. J. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3390\/molecules19021843","article-title":"Antiproliferative activity and induction of apoptosis in PC-3 cells by the chalcone cardamonin from Campomanesia adamantium (Myrtaceae) in a bioactivity-guided study","volume":"19","author":"Pascoal","year":"2014","journal-title":"Molecules"},{"key":"ref_181","first-page":"135","article-title":"Targeting prostate cancer stem cells for cancer therapy","volume":"13","author":"Wang","year":"2012","journal-title":"Discov. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00262-014-1592-1","article-title":"Cancer stem cells: Perspectives for therapeutic targeting","volume":"64","author":"Maccalli","year":"2015","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13046-025-03514-4","article-title":"The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: Implications and perspectives in cancer therapy","volume":"44","author":"Hussein","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12967-025-06176-0","article-title":"The integrative genomic and functional immunological analyses of colorectal cancer initiating cells to modulate stemness properties and the susceptibility to immune responses","volume":"23","author":"Tout","year":"2025","journal-title":"J. Transl. Med."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.18632\/oncotarget.2953","article-title":"Prostate cancer stem cells: Deciphering the origins and pathways involved in prostate tumorigenesis and aggression","volume":"6","author":"Rybak","year":"2015","journal-title":"Oncotarget"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1158\/0008-5472.CAN-16-2355","article-title":"Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer","volume":"77","author":"Wen","year":"2017","journal-title":"Cancer Res."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.biomaterials.2018.10.036","article-title":"Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer","volume":"192","author":"Lin","year":"2019","journal-title":"Biomaterials"},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Bartma\u0144ska, A., Tronina, T., Pop\u0142o\u0144ski, J., Milczarek, M., Filip-Psurska, B., and Wietrzyk, J. (2018). Highly Cancer Selective Antiproliferative Activity of Natural Prenylated Flavonoids. Molecules, 23.","DOI":"10.3390\/molecules23112922"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"e2000139","DOI":"10.1002\/cbdv.202000139","article-title":"Synthesis, Antiproliferative and Cytotoxic Activities, DNA Binding Features and Molecular Docking Study of Novel Enamine Derivatives","volume":"17","author":"Aydin","year":"2020","journal-title":"Chem. Biodivers."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"126760","DOI":"10.1016\/j.bmcl.2019.126760","article-title":"Synthesis of novel 4-Boc-piperidone chalcones and evaluation of their cytotoxic activity against highly-metastatic cancer cells","volume":"30","author":"Donate","year":"2020","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"424","DOI":"10.17843\/rpmesp.2021.383.6937","article-title":"Toxicity assessment of synthetic chalcones with antileishmanial potential in BALB\/c mice","volume":"38","author":"Cancino","year":"2021","journal-title":"Rev. Peru. Med. Exp. Salud Publica"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1021\/acs.jmedchem.8b01755","article-title":"Discovery of Novel Quinoline\u2013Chalcone Derivatives as Potent Antitumor Agents with Microtubule Polymerization Inhibitory Activity","volume":"62","author":"Li","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00210-022-02269-5","article-title":"[1,2,4] Triazolo [3,4-a]isoquinoline chalcone derivative exhibits anticancer activity via induction of oxidative stress, DNA damage, and apoptosis in Ehrlich solid carcinoma-bearing mice","volume":"395","author":"WalyEldeen","year":"2022","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_194","first-page":"4722","article-title":"Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK\/NF-kappaB and MAPK signaling pathways","volume":"24","author":"Zhou","year":"2010","journal-title":"FASEB J."},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Tronina, T., Bartma\u0144ska, A., Pop\u0142o\u0144ski, J., Rychlicka, M., Sordon, S., Filip-Psurska, B., Milczarek, M., Wietrzyk, J., and Huszcza, E. (2023). Prenylated Flavonoids with Selective Toxicity against Human Cancers. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087408"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s00044-019-02384-8","article-title":"Different reactivity to glutathione but similar tumor celltoxicity of chalcones and their quinolinone analogues","volume":"28","author":"Custodio","year":"2019","journal-title":"Med. Chem. Res."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/cmdc.200900499","article-title":"The tunable functionality of \u03b1,\u03b2-unsaturated carbonyl compounds enables their differential application in biological systems","volume":"5","author":"Amslinger","year":"2010","journal-title":"ChemMedChem"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"107601","DOI":"10.1016\/j.jddst.2025.107601","article-title":"Liposomal delivery of DK14 chalcone analogue: A promising therapeutic strategy against triple-negative breast cancer","volume":"115","author":"Suliman","year":"2026","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"109127","DOI":"10.1016\/j.bioorg.2025.109127","article-title":"ZnO nanoparticles enhance the cytotoxic effects of a chalcone-sulfonamide hybrid by impairing the autophagic flux and upregulating HIF-1\u03b1 expression","volume":"166","author":"Souza","year":"2025","journal-title":"Bioorganic Chem."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1080\/17568919.2025.2589717","article-title":"Development of new glycosyl-chalcones targeting cancer cells through recognition of cellular carbohydrate receptors","volume":"17","author":"Nakao","year":"2025","journal-title":"Future Med. Chem."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"126615","DOI":"10.1016\/j.bmcl.2019.08.019","article-title":"Anti-cancer potential of novel glycosylated 1,4-substituted triazolylchalcone derivatives","volume":"29","author":"Manna","year":"2019","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Toublet, F.-X., Laurent, A., and Pouget, C. (2025). A Review of Natural and Synthetic Chalcones as Anticancer Agents Targeting Topoisomerase Enzymes. Molecules, 30.","DOI":"10.3390\/molecules30122498"},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Adhikari, S., Nath, P., Deb, V.K., Das, N., Banerjee, A., Pathak, S., and Duttaroy, A.K. (2025). Pharmacological potential of natural chalcones: A recent studies and future perspective. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1570385"},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Laiche, M.H., and Barlow, J.W. (2025). Recent Advances in the Synthesis and Biological Applications of Prenylated Chalcones. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26209845"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2200684","DOI":"10.1002\/mnfr.202200684","article-title":"The Pharmacokinetics of Individual Conjugated Xanthohumol Metabolites Show Efficient Glucuronidation and Higher Bioavailability of Micellar than Native Xanthohumol in a Randomized, Double-Blind, Crossover Trial in Healthy Humans","volume":"67","author":"Buckett","year":"2023","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/jms.753","article-title":"Metabolism of xanthohumol and isoxanthohumol, prenylated flavonoids from hops (Humulus lupulus L.), by human liver microsomes","volume":"40","author":"Nikolic","year":"2005","journal-title":"J. Mass Spectrom. JMS"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.phrs.2016.01.011","article-title":"Versatile antitumor potential of isoxanthohumol: Enhancement of paclitaxel activity in vivo","volume":"105","author":"Wessjohann","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/ijc.25868","article-title":"Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling","volume":"129","author":"Sung","year":"2011","journal-title":"Int. J. Cancer"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1089\/ars.2011.4162","article-title":"Butein induces apoptosis and inhibits prostate tumor growth in vitro and in vivo","volume":"16","author":"Khan","year":"2012","journal-title":"Antioxid. Redox Signal."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0302-2838(03)00090-3","article-title":"Isoliquiritigenin inhibits the growth of prostate cancer","volume":"43","author":"Kanazawa","year":"2003","journal-title":"Eur. Urol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejphar.2017.12.053","article-title":"Antineoplastic activity of isoliquiritigenin, a chalcone compound, in androgen-independent human prostate cancer cells linked to G2\/M cell cycle arrest and cell apoptosis","volume":"821","author":"Zhang","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1440-1681.2010.05395.x","article-title":"Isoliquiritigenin, a natural anti-oxidant, selectively inhibits the proliferation of prostate cancer cells","volume":"37","author":"Zhang","year":"2010","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Lackova, Z., Buchtelova, H., Buchtova, Z., Klejdus, B., Heger, Z., Brtnicky, M., Kynicky, J., Zitka, O., and Adam, V. (2017). Anticarcinogenic Effect of Spices Due to Phenolic and Flavonoid Compounds-In Vitro Evaluation on Prostate Cells. Molecules, 22.","DOI":"10.3390\/molecules22101626"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1248\/cpb.56.1675","article-title":"Synthesis and cytotoxicity of novel 3-aryl-1-(3\u2032-dibenzylaminomethyl-4\u2032-hydroxyphenyl)-propenones and related compounds","volume":"56","author":"Gul","year":"2008","journal-title":"Chem. Pharm. Bull."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.toxrep.2014.02.002","article-title":"Dietary feeding of Flavokawain A, a Kava chalcone, exhibits a satisfactory safety profile and its association with enhancement of phase II enzymes in mice","volume":"1","author":"Li","year":"2014","journal-title":"Toxicol. Rep."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"41809","DOI":"10.18632\/oncotarget.6166","article-title":"Flavokawain A induces deNEDDylation and Skp2 degradation leading to inhibition of tumorigenesis and cancer progression in the TRAMP transgenic mouse model","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"ref_217","doi-asserted-by":"crossref","unstructured":"Song, L., Mino, M., Yamak, J., Nguyen, V., Lopez, D., Pham, V., Fazelpour, A., Le, V., Fu, D., and Tippin, M. (2022). Flavokawain A Reduces Tumor-Initiating Properties and Stemness of Prostate Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.943846"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/ijc.25210","article-title":"Flavokawain B, a kava chalcone, induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth","volume":"127","author":"Tang","year":"2010","journal-title":"Int. J. Cancer"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.taap.2013.10.031","article-title":"Pre-treatment with cardamonin protects against cisplatin-induced nephrotoxicity in rats: Impact on NOX-1, inflammation and apoptosis","volume":"274","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s10495-016-1313-7","article-title":"Cardamonin represses proliferation, invasion, and causes apoptosis through the modulation of signal transducer and activator of transcription 3 pathway in prostate cancer","volume":"22","author":"Zhang","year":"2017","journal-title":"Apoptosis"},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"6179","DOI":"10.3390\/molecules17066179","article-title":"Synthesis of chalcones with anticancer activities","volume":"17","author":"Syam","year":"2012","journal-title":"Molecules"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.bmcl.2011.12.141","article-title":"Methoxychalcone inhibitors of androgen receptor translocation and function","volume":"22","author":"Kim","year":"2012","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1158\/0008-5472.CAN-17-3728","article-title":"Targeting the Hsp40\/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer","volume":"78","author":"Moses","year":"2018","journal-title":"Cancer Res."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"101853","DOI":"10.1016\/j.redox.2021.101853","article-title":"Chalcone suppresses tumor growth through NOX4-IRE1\u03b1 sulfonation-RIDD-miR-23b axis","volume":"40","author":"Kim","year":"2021","journal-title":"Redox Biol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.phymed.2006.01.001","article-title":"Anti-proliferative properties of prenylated flavonoids from hops (Humulus lupulus L.) in human prostate cancer cell lines","volume":"13","author":"Delmulle","year":"2006","journal-title":"Phytomedicine"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1915828","DOI":"10.1155\/2018\/1915828","article-title":"Isobavachalcone Induces ROS-Mediated Apoptosis via Targeting Thioredoxin Reductase 1 in Human Prostate Cancer PC-3 Cells","volume":"2018","author":"Li","year":"2018","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.phymed.2006.11.027","article-title":"Cytotoxic and antiprotozoal activity of flavonoids from Lonchocarpus spp.","volume":"14","author":"Balnbury","year":"2007","journal-title":"Phytomedicine"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/10286020.2018.1450390","article-title":"Anti-inflammatory and antiproliferative prenylated chalcones from Hedysarum gmelinii","volume":"20","author":"Liu","year":"2018","journal-title":"J. Asian Nat. Prod. Res."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejmech.2017.03.077","article-title":"Novel 3\u2032,5\u2032-diprenylated chalcones inhibited the proliferation of cancer cells in vitro by inducing cell apoptosis and arresting cell cycle phase","volume":"133","author":"Wen","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"e1700076","DOI":"10.1002\/cbdv.201700076","article-title":"New cytotoxic alkylated chalcones from fatoua villosa","volume":"14","author":"Su","year":"2017","journal-title":"Chem. Biodivers."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"17715","DOI":"10.3390\/molecules191117715","article-title":"Synthesis and anti-tumor activity of novel aminomethylated derivatives of isoliquiritigenin","volume":"19","author":"Fu","year":"2014","journal-title":"Molecules"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"14070","DOI":"10.3390\/molecules181114070","article-title":"Design, synthesis and cytotoxic activities of novel aliphatic amino-substituted flavonoids","volume":"18","author":"Liu","year":"2013","journal-title":"Molecules"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1021\/jm800285f","article-title":"Inhibition of IkappaB kinase-beta and anticancer activities of novel chalcone adamantyl arotinoids","volume":"51","author":"Lorenzo","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/cmdc.201300100","article-title":"Adamantyl arotinoids that inhibit I\u03baB kinase \u03b1 and I\u03baB kinase \u03b2","volume":"8","author":"Lorenzo","year":"2013","journal-title":"ChemMedChem"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s11095-010-0347-8","article-title":"New 4-maleamic acid and 4-maleamide peptidyl chalcones as potential multitarget drugs for human prostate cancer","volume":"28","author":"Rodrigues","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1016\/j.bmcl.2017.08.024","article-title":"Design and multi-step synthesis of chalcone-polyamine conjugates as potent antiproliferative agents","volume":"27","author":"Rioux","year":"2017","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ardp.200600072","article-title":"Synthesis of 4\u2032-hydroxy-3\u2032-piperidinomethylchalcone derivatives and their cytotoxicity against PC-3 cell lines","volume":"340","author":"Gul","year":"2007","journal-title":"Arch. Pharm."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.1016\/j.bmc.2008.06.018","article-title":"Design, synthesis, and biological evaluation of Mannich bases of heterocyclic chalcone analogs as cytotoxic agents","volume":"16","author":"Reddy","year":"2008","journal-title":"Bioorganic Med. Chem."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1016\/j.bmc.2017.07.031","article-title":"Synthesis of different heterocycles-linked chalcone conjugates as cytotoxic agents and tubulin polymerization inhibitors","volume":"25","author":"Shankaraiah","year":"2017","journal-title":"Bioorganic Med. Chem."},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.bmc.2010.02.012","article-title":"Synthesis and biological evaluation of 2\u2032,5\u2032-dimethoxychalcone derivatives as microtubule-targeted anticancer agents","volume":"18","author":"Tu","year":"2010","journal-title":"Bioorganic Med. Chem."},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s11030-017-9768-1","article-title":"Synthesis and biological evaluation of glycosides containing triazene-chalcones","volume":"21","author":"Lei","year":"2017","journal-title":"Mol. Divers."},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1016\/j.bmcl.2016.10.029","article-title":"Design, synthesis and activity of novel sorafenib analogues bearing chalcone unit","volume":"26","author":"Wang","year":"2016","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.fct.2015.11.016","article-title":"A novel quinazolinone chalcone derivative induces mitochondrial dependent apoptosis and inhibits PI3K\/Akt\/mTOR signaling pathway in human colon cancer HCT-116 cells","volume":"87","author":"Wani","year":"2016","journal-title":"Food Chem. Toxicol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"4865","DOI":"10.1016\/j.bmcl.2010.06.097","article-title":"Synthesis and anti-cancer activity of chalcone linked imidazolones","volume":"20","author":"Kamal","year":"2010","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ejmech.2011.10.033","article-title":"1,2,3-Triazole tethered \u03b2-lactam-chalcone bifunctional hybrids: Synthesis and anticancer evaluation","volume":"47","author":"Singh","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"127454","DOI":"10.1016\/j.bmcl.2020.127454","article-title":"2H-1,2,3-Triazole-chalcones as novel cytotoxic agents against prostate cancer","volume":"30","author":"Pinheiro","year":"2020","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1080\/15384101.2016.1160980","article-title":"Novel indolyl-chalcones target stathmin to induce cancer cell death","volume":"15","author":"Wegiel","year":"2016","journal-title":"Cell Cycle"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1016\/j.bmcl.2016.10.063","article-title":"Novel synthetic chalcones induce apoptosis in the A549 non-small cell lung cancer cells harboring a KRAS mutation","volume":"26","author":"Wang","year":"2016","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1039\/C7MD00193B","article-title":"Synthesis and biological evaluation of chalcone-linked pyrazolo [1,5-a]pyrimidines as potential anticancer agents","volume":"8","author":"Bagul","year":"2017","journal-title":"Medchemcomm"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.1016\/j.bmcl.2010.09.041","article-title":"Synthesis and anticancer evaluation of thiazolyl-chalcones","volume":"20","author":"Shi","year":"2010","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/cmdc.201402310","article-title":"Design and synthesis of imidazo[2,1-b]thiazole-chalcone conjugates: Microtubule-destabilizing agents","volume":"9","author":"Kamal","year":"2014","journal-title":"ChemMedChem"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"7877","DOI":"10.1021\/acs.jmedchem.8b00827","article-title":"Structural modification of the 3,4,5-trimethoxyphenyl moiety in the tubulin inhibitor VERU-111 leads to improved antiproliferative activities","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1016\/j.bmcl.2012.05.016","article-title":"Synthesis and selective cytotoxic activity of novel hybrid chalcones against prostate cancer cells","volume":"22","author":"Nagaraju","year":"2012","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejmech.2017.05.017","article-title":"Novel 1-(7-ethoxy-1-benzofuran-2-yl) substituted chalcone derivatives: Synthesis, characterization and anticancer activity","volume":"136","author":"Coskun","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1590\/S0100-879X2012007500022","article-title":"In vitro anti-inflammatory, cytotoxic and antioxidant activities of boesenbergin A, a chalcone isolated from Boesenbergia rotunda (L.) (fingerroot)","volume":"45","author":"Isa","year":"2012","journal-title":"Braz. J. Med. Biol. Res."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ejmech.2015.02.027","article-title":"Synthesis, docking and ADMET studies of novel chalcone triazoles for anti-cancer and anti-diabetic activity","volume":"93","author":"Chinthala","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_257","doi-asserted-by":"crossref","unstructured":"Pop\u0142o\u0144ski, J., Turlej, E., Sordon, S., Tronina, T., Bartma\u0144ska, A., Wietrzyk, J., and Huszcza, E. (2018). Synthesis and Antiproliferative Activity of Minor Hops Prenylflavonoids and New Insights on Prenyl Group Cyclization. Molecules, 23.","DOI":"10.3390\/molecules23040776"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ejmech.2011.10.026","article-title":"Bis-chalcone analogues as potent NO production inhibitors and as cytotoxic agents","volume":"47","author":"Shen","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1021\/acs.jnatprod.7b00736","article-title":"Structurally diverse cytotoxic dimeric chalcones from Oxytropis chiliophylla","volume":"81","author":"Liu","year":"2018","journal-title":"J. Nat. Prod."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ejmech.2014.02.021","article-title":"Antiobesity, antioxidant and cytotoxicity activities of newly synthesized chalcone derivatives and their metal complexes","volume":"76","author":"Saleh","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/1573406413666171020121244","article-title":"Design, Synthesis, and Evaluation of (2-(Pyridinyl)methylene)-1-tetralone Chalcones for Anticancer and Antimicrobial Activity","volume":"14","author":"Gibson","year":"2018","journal-title":"Med. Chem."},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1039\/C9MD00127A","article-title":"Synthesis and biological evaluation of structurally diverse \u03b1-conformationally restricted chalcones and related analogues","volume":"10","author":"Maguire","year":"2019","journal-title":"Medchemcomm"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/1871526519666181217120626","article-title":"Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents","volume":"19","author":"Lokesh","year":"2019","journal-title":"Infect. Disord. Drug Targets"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12082\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T09:59:02Z","timestamp":1765879142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/24\/12082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":263,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["ijms262412082"],"URL":"https:\/\/doi.org\/10.3390\/ijms262412082","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}